Voyager Therapeutics Inc (VYGR.OQ)
25 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2014||Independent Chairman of the Board|
|66||2014||President, Chief Executive Officer, Director|
|51||2017||Chief Financial Officer, Senior Vice President|
|46||2017||Chief Operating Officer|
|69||2014||Senior Vice President - Regulatory Affairs|
- BRIEF-Voyager Therapeutics Reports Q4 GAAP Loss Per Share $0.40
- BRIEF-Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease
- BRIEF-Voyager Therapeutics And Abbvie Announce Global Strategic Collaboration
- BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC
- BRIEF-Ophthotech Announces Election Of Jane Pritchett Henderson, CFO And Senior Vice President Of Corporate Development At Voyager Therapeutics, To Its Board Of Directors